The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Open accessAbstract
Objective To describe the effects of treatment for 1 year with ranibizumab or bevacizumab on macular morphology and the association of macular morphology with visual acuity (VA) in eyes with neovascular age-related macular degeneration (AMD).Design Prospective cohort study within a randomized clinical trial.Participants Participants in the Comparison of Age-related Macular Degeneration Treatments Trials.Methods Participants were assigned randomly to treatment with ranibizumab or bevacizumab on a monthly or as-needed schedule. Optical coherence tomography (OCT), fluorescein angiography (FA), color fundus photography (FP), and VA testing were performed periodically throughout 52 weeks. Masked readers graded images. General linear models were applied to evaluate effects of time and treatment on outcomes.Main outcome measures Fluid type and location and thickness by OCT, size, and lesion composition on FP, FA, and VA.Results Intraretinal fluid (IRF), subretinal fluid (SRF), subretinal pigment epithelium fluid, and retinal, subretinal, and subretinal tissue complex thickness decreased in all treatment groups. A higher proportion of eyes treated monthly with ranibizumab had fluid resolution at 4 weeks, and the difference persisted through 52 weeks. At 52 weeks, there was little association between the presence of fluid of any type (without regard to fluid location) and the mean VA. However, at all time points, eyes with residual IRF, especially foveal IRF, had worse mean VA (9 letters) than those without IRF. Eyes with abnormally thin (<120 μm) or thick (>212 μm) retinas had worse VA than those with normal thickness (120-212 μm). At week 52, eyes with larger neovascular lesions or with foveal scar had worse VA than eyes without these features.Conclusions Anti-vascular endothelial growth factor (VEGF) therapy reduced lesion activity and improved VA in all treatment groups. At all time points, eyes with residual IRF had worse VA than those without. Eyes with abnormally thin or thick retinas, residual large lesions, and scar also had worse VA. Monthly ranibizumab dosing yielded more eyes with no fluid and an abnormally thin retina, although the long-term significance is unknown. These results have important treatment implications in eyes undergoing anti-VEGF therapy for neovascular AMD.Financial disclosure(s) Proprietary or commercial disclosure may be found after the references.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subretinal and retinal scarring are associated with profound vision loss and are natural outcomes of neovascular age-related macular degeneration (nvAMD).1–4”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The response to anti-VEGF therapy have been found to be dependent on a variety of factors including patient's age, lesion characteristics, lesion duration, baseline visual acuity (VA) and the presence of particular genotype risk alleles.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a previous CATT report, we described a strong association between decreased visual acuity at the end of 1 year and the presence of intraretinal fluid but not subretinal or sub-RPE fluid on OCT.1”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, the morphological outcomes may also vary from complete resolution of the lesion to a fibrovascular scar despite presumed adequate monitoring of the disease.14”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [14]
In the citing paper
“We previously reported that retinal thinning to <120 microns was associated with worse VA outcomes at 1 and 2 years.36,37”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [36]
In the citing paper
“On a cross-sectional basis, the presence of intraretinal fluid is associated with worse visual acuity during anti-VEGF treatment while the presence of subretinal fluid is associated with better visual acuity.36–38”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citationA computerized method of visual acuity testing
Beck, R. W., Moke, P. S., Turpin, A. H., Ferris, F. L., SanGiovanni, J. P., Johnson, C. A., Birch, E. E., Chandler, D. L., Cox, T. A., Blair, R. C., et al. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01825-1 · Cited by 613
Normal Macular Thickness Measurements in Healthy Eyes Using Stratus Optical Coherence Tomography
Chan, A. Y. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.2.193 · Cited by 425
ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Brown, D., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., & Kim, R. Y. (2006) · Cited by 382
Ying, G.-S., Huang, J., Maguire, M. G., Jaffe, G. J., Grunwald, J. E., Toth, C., Daniel, E., Klein, M., Pieramici, D., Wells, J., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.042 · Cited by 305
Self-citationKaiser, P. K., Blodi, B. A., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.04.030 · Cited by 219
Cited by
Sorted by citations
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Self-citationRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Self-citationAnti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Age-related macular degeneration
Guymer, R. H., & Campbell, T. G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02609-5 · Cited by 541
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
Dugel, P. U., Singh, R. P., Koh, A., Ogura, Y., Weissgerber, G., Gedif, K., Jaffe, G. J., Tadayoni, R., Schmidt-Erfurth, U. M., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.06.028 · Cited by 382
Self-citationDefining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Self-citationGuymer, R. H., Markey, C. M., McAllister, I. L., Gillies, M. C., Hunyor, A. P., Arnold, J. J., Chang, A., Syed, A., Broadhead, G., Pham, T., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.025 · Cited by 317
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K. B., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 280
Jaffe, G. J., Ying, G., Toth, C. A., Daniel, E., Grunwald, J. E., Martin, D. F., & Maguire, M. G. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.035 · Cited by 248
Self-citationSharma, S., Toth, C. A., Daniel, E., Grunwald, J. E., Maguire, M. G., Ying, G.-S., Huang, J., Martin, D. F., & Jaffe, G. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.002 · Cited by 231
Self-citationWilloughby, A. S., Ying, G., Toth, C. A., Maguire, M. G., Burns, R. E., Grunwald, J. E., Daniel, E., Jaffe, G. J., Williams, D. F., Beardsley, S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.042 · Cited by 224
Self-citationBhisitkul, R. B., Mendes, T. S., Rofagha, S., Enanoria, W., Boyer, D. S., Sadda, S. R., & Zhang, K. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.032 · Cited by 210
Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.012 · Cited by 214
Self-citationSchmidt-Erfurth, U., Waldstein, S. M., Deak, G.-G., Kundi, M., & Simader, C. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.017 · Cited by 211
Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Ying, G., Maguire, M. G., Daniel, E., & Martín, D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.007 · Cited by 207
Self-citationSchmidt-Erfurth, U. M., Bogunović, H., Sadeghipour, A., Schlegl, T., Langs, G., Gerendas, B. S., Osborne, A. R., & Waldstein, S. M. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.015 · Cited by 201
Schmidt-Erfurth, U. M., Klimscha, S., Waldstein, S. M., & Bogunović, H. (2016) · Eye · doi:10.1038/eye.2016.227 · Cited by 182
Waldstein, S. M., Simader, C., Staurenghi, G., Chong, V. N., Mitchell, P., Jaffe, G. J., Lu, C., Katz, T. A., & Schmidt-Erfurth, U. M. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.037 · Cited by 173
Self-citationSchmidt-Erfurth, U. M., Vogl, W., Jampol, L. M., & Bogunović, H. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.010 · Cited by 159
Evans, R. N., Reeves, B. C., Maguire, M. G., Martin, D. F., Muldrew, A., Peto, T., Rogers, C., & Chakravarthy, U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.3001 · Cited by 145
Self-citationQuantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning
Moraes, G., Fu, D. J., Wilson, M., Khalid, H., Wagner, S. K., Korot, E., Ferraz, D., Faes, L., Kelly, C. J., Spitz, T., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.09.025 · Cited by 130
Waldstein, S. M., Wright, J., Warburton, J., Margaron, P., Simader, C., & Schmidt-Erfurth, U. M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.013 · Cited by 132
Waldstein, S. M., Philip, A.-M., Leitner, R., Simader, C., Langs, G., Gerendas, B. S., & Schmidt-Erfurth, U. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4948 · Cited by 110
Towards a better understanding of non-exudative choroidal and macular neovascularization
Sacconi, R., Fragiotta, S., Sarraf, D., Sadda, S. R., Freund, K. B., Parravano, M., Corradetti, G., Cabral, D., Capuano, V., Mière, A., et al. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101113 · Cited by 113
Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ying, G., Kim, B. J., Maguire, M. G., Huang, J., Daniel, E., Jaffe, G. J., Grunwald, J. E., Blinder, K. J., Flaxel, C. J., Rahhal, F. M., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1019 · Cited by 108
Self-citationCho, H. J., Yoo, S. G., Kim, H. S., Kim, J. H., Kim, C. G., Lee, T. G., & Kim, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.10.035 · Cited by 102
AI-based monitoring of retinal fluid in disease activity and under therapy
Schmidt-Erfurth, U. M., Reiter, G. S., Riedl, S., Seeböck, P., Vogl, W., Blodi, B. A., Domalpally, A., Fawzi, A. A., Jia, Y., Sarraf, D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100972 · Cited by 105
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
Kunimoto, D., Yoon, Y. H., Wykoff, C. C., Chang, A., Khurana, R. N., Maturi, R. K., Agostini, H., Souied, E., Chow, D. R., Lotery, A. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.035 · Cited by 91
Schütze, C., Wedl, M., Baumann, B., Pircher, M., Hitzenberger, C. K. F., & Schmidt-Erfurth, U. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.02.020 · Cited by 90
OCT Biomarkers in Neovascular Age‐Related Macular Degeneration: A Narrative Review
Metrangolo, C., Donati, S., Mazzola, M., Fontanel, L., Messina, W., D’alterio, G., Rubino, M., Radice, P., Premi, E., & Azzolini, C. (2021) · Journal of Ophthalmology · doi:10.1155/2021/9994098 · Cited by 89
Ritter, M., Simader, C., Bolz, M., Deák, G. G., Sponer, U., Sayegh, R. G., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305186 · Cited by 88
Amer, R., Nalcı, H., & Yalçındağ, F. N. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.05.001 · Cited by 86
Ou, W. C., Brown, D. M., Payne, J. F., & Wykoff, C. C. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.05.014 · Cited by 83
Gianniou, C., Dirani, A., Jang, L., & Mantel, I. (2015) · Retina · doi:10.1097/iae.0000000000000465 · Cited by 81
Jaffe, G. J., Kaiser, P. K., Thompson, D. E., Gibson, A., Saroj, N., Vitti, R., Berliner, A. J., & Heier, J. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.05.016 · Cited by 79
Self-citationThe potential of spectral domain optical coherence tomography imaging based retinal biomarkers
Phadikar, P., Saxena, S., Ruia, S., Lai, T. Y. Y., Meyer, C. H., & Eliott, D. (2017) · International Journal of Retina and Vitreous · doi:10.1186/s40942-016-0054-7 · Cited by 78
Liu, Y., Holekamp, N. M., & Heier, J. S. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.02.011 · Cited by 77
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 76
Self-citationMatsuda, Y., Nonaka, Y., Futakawa, S., Imai, H., Akita, K., Nishihata, T., Fujiwara, M., Ali, Y., Bhisitkul, R. B., & Nakamura, Y. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.07.018 · Cited by 73
Kaiser, P. K., Wykoff, C. C., Singh, R. P., Khanani, A. M., Diana, V., Patel, H., & Patel, N. (2021) · Retina · doi:10.1097/iae.0000000000003194 · Cited by 73
Callanan, D., Kunimoto, D., Maturi, R. K., Patel, S. S., Staurenghi, G., Wolf, S., Cheetham, J. K., Hohman, T. C., Kim, K., López, F. J., et al. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0062 · Cited by 73
Ross, A. H., Downey, L., Devonport, H., Gale, R. P., Kotagiri, A. K., Mahmood, S., Mehta, H., Narendran, N., Patel, P. J., Parmar, N., et al. (2020) · Eye · doi:10.1038/s41433-019-0747-x · Cited by 68
Cheung, C. M. G., Grewal, D. S., Teo, K. Y. C., Gan, A. T. L., Mohla, A., Chakravarthy, U., Wong, T. Y., & Jaffe, G. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.06.002 · Cited by 65
Self-citationGeographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review
Kaszubski, P. A., Ami, T. B., Saade, C., & Smith, R. T. (2016) · Ophthalmic Research · doi:10.1159/000443209 · Cited by 62
Sidman, R. L., Li, J., Lawrence, M. S., Hu, W., Musso, G. F., Giordano, R. J., Cardó‐Vila, M., Pasqualini, R., & Arap, W. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4882 · Cited by 61
IDENTIFYING FEATURES OF EARLY AND LATE AGE-RELATED MACULAR DEGENERATION
Graham, K. W., Chakravarthy, U., Hogg, R. E., Muldrew, K. A., Young, I. S., & Kee, F. (2017) · Retina · doi:10.1097/iae.0000000000001777 · Cited by 62
Chakravarthy, U., Pillai, N., Syntosi, A., Barclay, L., Best, C., & Sagkriotis, A. (2020) · Eye · doi:10.1038/s41433-020-0799-y · Cited by 61
Chaudhary, V., Matonti, F., Zarranz‐Ventura, J., & Stewart, M. W. (2021) · Retina · doi:10.1097/iae.0000000000003283 · Cited by 60
Lee, H., Kang, K. E., Chung, H., & Kim, H. C. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.04.007 · Cited by 60
Kodjikian, L., Parravano, M., Clemens, A., Dolz‐Marco, R., Holz, F. G., Munk, M. R., Nicolò, M., Ricci, F., da Silva, R. M., Talks, J. S., et al. (2021) · Eye · doi:10.1038/s41433-021-01487-0 · Cited by 57
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials
Ying, G., Maguire, M. G., Pan, W., Grunwald, J. E., Daniel, E., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., & Martín, D. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.10.003 · Cited by 59
Self-citationMantel, I., Mosinska, A., Bergin, C., Polito, M. S., Guidotti, J. M., Apostolopoulos, S., Ciller, C., & Zanet, S. I. D. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.17 · Cited by 56
Ristau, T., Keane, P. A., Walsh, A. C., Engin, A., Mokwa, N., Kirchhof, B., Sadda, S. R., & Liakopoulos, S. (2013) · Ophthalmologica · doi:10.1159/000354551 · Cited by 55
Sharma, S., Khan, M. A., Chaturvedi, A., & RE-ENACT Study Investigators Group (2018) · Ophthalmologica · doi:10.1159/000488602 · Cited by 54
Dirani, A., Ambresin, A., Marchionno, L., Decugis, D., & Mantel, I. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.06.025 · Cited by 52
Reiter, G. S., Grechenig, C., Vogl, W., Guymer, R. H., Arnold, J., Bogunović, H., & Schmidt-Erfurth, U. M. (2020) · Retina · doi:10.1097/iae.0000000000003023 · Cited by 50
Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial
Riedl, S., Vogl, W., Waldstein, S. M., Schmidt-Erfurth, U. M., & Bogunović, H. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.12.007 · Cited by 50
Abbas, Q., Qureshi, I., Yan, J., & Shaheed, K. (2022) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-022-09720-z · Cited by 50
Kim, J. H., Chang, Y. S., & Kim, J. W. (2017) · Retina · doi:10.1097/iae.0000000000001494 · Cited by 50
Kumar, J. B., Stinnett, S. S., Han, J. I., & Jaffe, G. J. (2019) · Retina · doi:10.1097/iae.0000000000002552 · Cited by 49
Self-citationA novel peptide specifically binding to VEGF receptor suppresses angiogenesis in vitro and in vivo
Zhang, Y., He, B., Liu, K., Lin, N., Luo, D., Xu, K., Zhu, W., Wu, Z., Huang, J. H., & Xu, X. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.10 · Cited by 49
Self-citationFu, D. J., Faes, L., Wagner, S. K., Moraes, G., Chopra, R., Patel, P. J., Balaskas, K., Keenan, T. D. L., Bachmann, L. M., & Keane, P. A. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.01.009 · Cited by 48
Michl, M., Fabianska, M., Seeböck, P., Sadeghipour, A., Najeeb, B. H., Bogunović, H., Schmidt-Erfurth, U. M., & Gerendas, B. S. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317416 · Cited by 48
Aslam, T. M., Zaki, H. R., Mahmood, S., Ali, Z. C., Ahmad, N. A., Thorell, M. R., & Balaskas, K. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.10.015 · Cited by 44
Low, A., Faridi, A., Bhavsar, K. V., Cockerham, G. C., Freeman, M., Fu, R., Paynter, R. A., Kondo, K. K., & Kansagara, D. L. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312691 · Cited by 45
Hoerster, R., Muether, P. S., Sitnilska, V., Kirchhof, B., & Fauser, S. (2014) · Retina · doi:10.1097/iae.0000000000000188 · Cited by 43
Riedl, S., Waldstein, S. M., Schlegl, T., Bogunović, H., Sadeghipour, A., Philip, A.-M., Podkowinski, D., Pablik, E., Zhang, L., Abràmoff, M. D., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20201 · Cited by 40
Sharma, S., Khan, M. A., Chaturvedi, A., & RE-ENACT 2 Study Investigators Group (2019) · Ophthalmology and Therapy · doi:10.1007/s40123-019-00228-7 · Cited by 40
Khurana, R. N., Kunimoto, D. Y., Yoon, Y. H., Wykoff, C. C., Chang, A., Maturi, R. K., Agostini, H. T., Souied, E. H., Chow, D. R., Lotery, A. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.017 · Cited by 41
Folgar, F. A., Jaffe, G. J., Ying, G., Maguire, M. G., & Toth, C. A. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.020 · Cited by 39
Self-citationCheong, K. X., Teo, K. Y. C., & Cheung, C. M. G. (2020) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.05.003 · Cited by 39
Ohji, M., Okada, A. A., Sasaki, K., Moon, S. C., Machewitz, T., Takahashi, K. A., & the ALTAIR Investigators (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05293-y · Cited by 39
Kawczynski, M. G., Bengtsson, T., Dai, J., Hopkins, J. J., Gao, S. S., & Willis, J. R. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.2.51 · Cited by 36
Grechenig, C., Reiter, G. S., Riedl, S., Arnold, J., Guymer, R. H., Gerendas, B. S., Bogunović, H., & Schmidt-Erfurth, U. M. (2021) · Retina · doi:10.1097/iae.0000000000003180 · Cited by 36
Yeh, T.-C., Luo, A.-C., Deng, Y.-S., Lee, Y.-H., Chen, S., Chang, P.-H., Lin, C., Tai, M.-C., & Chou, Y.-B. (2022) · Scientific Reports · doi:10.1038/s41598-022-09642-7 · Cited by 36
Rasmussen, A., & Sander, B. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000050 · Cited by 35
Siedlecki, J., Fischer, C., Schworm, B., Kreutzer, T. C., Luft, N., Kortuem, K., Schumann, R. G., Wolf, A., & Priglinger, S. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-64901-9 · Cited by 34
Roberts, P. K., Mittermüller, T. J., Montuoro, A., Sulzbacher, F., Munk, M. R., Sacu, S., & Schmidt-Erfurth, U. M. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14293 · Cited by 33
Lee, H., Jo, A., & Kim, H. C. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20637 · Cited by 33
Nguyen, V., Barthelmes, D., & Gillies, M. C. (2021) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13949 · Cited by 32
Ehlers, J. P., Patel, N., Kaiser, P. K., Heier, J. S., Brown, D. M., Meng, X., Reese, J. L., Lunasco, L. M., Le, T. K., Hu, M., et al. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.6.17 · Cited by 32
Wang, W., & Zhang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109744 · Cited by 31
OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization
Sacconi, R., Forte, P., Tombolini, B., Grosso, D., Fantaguzzi, F., Pina, A., Querques, L., Bandello, F. M., & Querques, G. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.02.010 · Cited by 32
Khurana, R. N., Rahimy, E., Joseph, W. A., Saroj, N., Gibson, A., Vitti, R., Berliner, A. J., Chu, K. W., Cheng, Y., & Boyer, D. S. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.01.005 · Cited by 30
Fang, M., Chanwimol, K., Maram, J., O’Keefe, G. A. D., Wykoff, C. C., Sarraf, D., Brown, A., Lampen, S. I. R., Zhou, B., Rusakevich, A. M., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319602 · Cited by 31
Bhavsar, K. V., & Freund, K. B. (2014) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2014.03.001 · Cited by 29
Parravano, M., Tedeschi, M., Manca, D., Costanzo, E., Renzo, A. D., Giorno, P., Barbano, L., Ziccardi, L., Varano, M., & Parisi, V. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01016-2 · Cited by 28
Kodjikian, L., Decullier, É., Souied, E. H., Roux, A. S., Aulagner, G., Huot, L., & for the GEFAL Study Group (2017) · Retina · doi:10.1097/iae.0000000000001736 · Cited by 27
Ogasawara, M., Koizumi, H., Yamamoto, A., Itagaki, K., Saito, M., Maruko, I., Okada, A. A., Iida, T., & Sekiryu, T. (2018) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-018-0605-6 · Cited by 27
Alex, D., Anantharaman, G., Gopalakrishnan, M., Indurkhya, S., & Madan, S. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3156_20 · Cited by 27
Daniel, E., Ying, G., Kim, B. J., Toth, C. A., Ferris, F. L., Martin, D. F., Grunwald, J. E., Jaffe, G. J., Dunaief, J. L., Pan, W., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.020 · Cited by 26
Self-citationCheong, K. X., Grewal, D. S., Teo, K. Y. C., Gan, A. T. L., Jaffe, G. J., & Cheung, C. M. G. (2020) · Eye · doi:10.1038/s41433-020-0803-6 · Cited by 27
Self-citationHata, M., Yamashiro, K., Oishi, A., Ooto, S., Tamura, H., Miyata, M., Ueda‐Arakawa, N., Kuroda, Y., Takahashi, A., Tsujikawa, A., et al. (2017) · Retina · doi:10.1097/iae.0000000000001457 · Cited by 27
Toth, C. A., Tai, V., Pistilli, M., Chiu, S. J., Winter, K. P., Daniel, E., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Ying, G., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.11.011 · Cited by 25
Self-citationSadda, S. R., Holekamp, N. M., Sarraf, D., Ebraheem, A., Fan, W., Hill, L., Blotner, S., Spicer, G. J., & Gune, S. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05716-4 · Cited by 25
Kim, J. H., Sagong, M., Woo, S. J., Kim, Y. C., Cho, H., Lee, Y. H., Byon, I. S., Jo, Y. J., Chin, H. S., Lee, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18158-z · Cited by 26
Long-term natural history of idiopathic epiretinal membranes with good visual acuity
Luu, K.-Y., Koenigsaecker, T., Yazdanyar, A., Mukkamala, L. K., Durbin-Johnson, B. P., Morse, L. S., Moshiri, A., Park, S. S., & Yiu, G. C. (2019) · Eye · doi:10.1038/s41433-019-0397-z · Cited by 24
Finn, A. P., Pistilli, M., Tai, V., Daniel, E., Ying, G., Maguire, M. G., Grunwald, J. E., Martin, D. F., Jaffe, G. J., & Toth, C. A. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.11.002 · Cited by 23
Self-citation
Metadata
- Authors
- Jaffe, G. J., Martin, D. F., Toth, C. A., Daniel, E., Maguire, M. G., Ying, G.-S., Grunwald, J. E., & Huang, J.
- Affiliations
- Duke University (US)
- Cleveland Clinic (US)
- University of Pennsylvania (US)
- Corresponding author
- Jaffe, Glenn J.
- ORCID
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 120
- Issue
- 9
- Pages
- 1860-1870
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC3737287
- OpenAlex
- W2074575505
- Cited by
- 294
- References
- 15
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 26 · 2023: 16 · 2022: 29 · 2021: 38 · 2020: 27 · 2019: 21 · 2018: 23 · 2017: 24 · 2016: 17 · 2015: 15 · 2014: 15 · 2013: 5
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, anti-VEGF therapy, macular morphology, visual acuity, intraretinal fluid, subretinal fluid, retinal thickness, lesion activity, macular edema
- MeSH terms
- Bevacizumab, Ranibizumab, Fluorescein Angiography, Follow-Up Studies, Humans, Macula Lutea, Macular Degeneration, Prospective Studies, Visual Acuity, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Subretinal Fluid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
